As of May 1, a new reimbursement list takes effect. The announcement introduces many important changes for patients. Deputy Health Minister Maciej Miłkowski tells what drugs are on the list and what therapies we can expect to see on the next reimbursement list in July.
Majowa lista leków refundowanych. O zmianach dla pacjentów mówi Maciej Miłkowski
Published May 1, 2023 09:00
Fot. Anna Sincini
The reimbursement notice effective May 1, 2023 (No. 69), compared to Notice No. 68, contains the following changes:
1 A total of 111 products or new indications were added to the list due to positive reimbursement decisions.
2. reductions in official selling prices (from PLN 0.05 to PLN 2,430.00) were introduced for 37 products.
3 For 47 products, official selling prices were increased (from PLN 0.03 to PLN 37.56).
4 For 316 items in the announcement, the patient surcharge will decrease (from PLN 0.01 to PLN 196.80).
5 For 432 items in the announcement, the patient surcharge will increase (from PLN 0.01 to PLN 452.70).
6. for 184 products will be reduced gross retail prices (from PLN 0.01 to 384.10).
7 For 131 products, gross retail prices will increase (from PLN 0.01 to PLN 40.43).
(8) Due to the receipt of applications to shorten the term of reimbursement decisions or the expiration of the term of reimbursement decisions or refusal of reimbursement for the next period, the announcement will not include 26 products or indications listed in the previous announcement.
INFORMATION ON MEDICINE PROGRAM B.3 and B.53.
According to the April 20, 2023 announcement by the Minister of Health on the list of reimbursed drugs, foodstuffs for special nutritional purposes and medical devices as of May 1, 2023, imatinib, everolimus, sorafenib and sunitinib medicinal products are transferred from currently reimbursed drug programs:
- B.3 - TREATMENT OF GASTROINTESTINAL LINING TUMORS (GIST) (ICD-10 C 15, C 16, C 17, C 18, C 20, C 48),
- B.5 - TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (ICD-10: C22.0),
- B.8 - TREATMENT OF PATIENTS WITH SOFT TISSUE SARCOMAS (ICD-10: C48, C49),
- B.10 - TREATMENT OF PATIENTS WITH RENAL CELL CARCINOMA (ICD-10: C64),
- B.53 - TREATMENT OF HIGHLY DIFFERENTIATED NEUROENDOCRIC TROUBLE (ICD-10 C25.4) to the chemotherapy catalog.
Due to the fact that all therapies currently reimbursed under drug program B.3 - TREATMENT OF Gastrointestinal Stem Tumors (GIST) (ICD-10 C 15, C 16, C 17, C 18, C 20, C 48) and B.53 - TREATMENT OF HIGHLY DIFFERENTIATED NEUROENDOCRIC TROUBLE (GIST) TREATMENT (ICD-10 C25.4) therapies, are subject to a change in reimbursement availability category and are moved to the respective chemotherapy catalogs, with drug programs B.3 and B.53 discontinued as of May 2023.
Source: MZ
